Literature DB >> 16370392

EndoTAG-1. MediGene.

Gunter Schuch1.   

Abstract

MediGene is developing EndoTAG-1, a formulation of paclitaxel encapsulated in positively charged lipid-based complexes, for the potential treatment of cancer. Phase II clinical trials in patients with advanced pancreatic cancer are ongoing.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16370392

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  7 in total

Review 1.  Microtubule targeting agents: from biophysics to proteomics.

Authors:  D Calligaris; P Verdier-Pinard; F Devred; C Villard; D Braguer; Daniel Lafitte
Journal:  Cell Mol Life Sci       Date:  2010-01-28       Impact factor: 9.261

Review 2.  Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics.

Authors:  Long Xu; Thomas Anchordoquy
Journal:  J Pharm Sci       Date:  2011-01       Impact factor: 3.534

Review 3.  Targeting anticancer drugs to tumor vasculature using cationic liposomes.

Authors:  Amr S Abu Lila; Tatsuhiro Ishida; Hiroshi Kiwada
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

Review 4.  Tubulin-interactive natural products as anticancer agents.

Authors:  David G I Kingston
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

Review 5.  Liposomal Formulations in Clinical Use: An Updated Review.

Authors:  Upendra Bulbake; Sindhu Doppalapudi; Nagavendra Kommineni; Wahid Khan
Journal:  Pharmaceutics       Date:  2017-03-27       Impact factor: 6.321

Review 6.  Cationic Surfactants: Self-Assembly, Structure-Activity Correlation and Their Biological Applications.

Authors:  Lucia Ya Zakharova; Tatiana N Pashirova; Slavomira Doktorovova; Ana R Fernandes; Elena Sanchez-Lopez; Amélia M Silva; Selma B Souto; Eliana B Souto
Journal:  Int J Mol Sci       Date:  2019-11-06       Impact factor: 5.923

Review 7.  Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma.

Authors:  Junjie Li; Fengyong Liu; Sanjay Gupta; Chun Li
Journal:  Theranostics       Date:  2016-06-15       Impact factor: 11.556
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.